392 related articles for article (PubMed ID: 19760604)
1. Two candidate tumor suppressor genes, MEOX2 and SOSTDC1, identified in a 7p21 homozygous deletion region in a Wilms tumor.
Ohshima J; Haruta M; Arai Y; Kasai F; Fujiwara Y; Ariga T; Okita H; Fukuzawa M; Hata J; Horie H; Kaneko Y
Genes Chromosomes Cancer; 2009 Dec; 48(12):1037-50. PubMed ID: 19760604
[TBL] [Abstract][Full Text] [Related]
2. Loss of heterozygosity at 7p in Wilms' tumour development.
Powlesland RM; Charles AK; Malik KT; Reynolds PA; Pires S; Boavida M; Brown KW
Br J Cancer; 2000 Jan; 82(2):323-9. PubMed ID: 10646884
[TBL] [Abstract][Full Text] [Related]
3. Loss of heterozygosity and SOSTDC1 in adult and pediatric renal tumors.
Blish KR; Clausen KA; Hawkins GA; Garvin AJ; Willingham MC; Turner JC; Torti FM; Torti SV
J Exp Clin Cancer Res; 2010 Nov; 29(1):147. PubMed ID: 21080955
[TBL] [Abstract][Full Text] [Related]
4. Mapping of a putative tumor suppressor locus to proximal 7p in Wilms tumors.
Miozzo M; Perotti D; Minoletti F; Mondini P; Pilotti S; Luksch R; Fossati-Bellani F; Pierotti MA; Sozzi G; Radice P
Genomics; 1996 Nov; 37(3):310-5. PubMed ID: 8938443
[TBL] [Abstract][Full Text] [Related]
5. Association of 11q loss, trisomy 12, and possible 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor.
Watanabe N; Nakadate H; Haruta M; Sugawara W; Sasaki F; Tsunematsu Y; Kikuta A; Fukuzawa M; Okita H; Hata J; Soejima H; Kaneko Y
Genes Chromosomes Cancer; 2006 Jun; 45(6):592-601. PubMed ID: 16518847
[TBL] [Abstract][Full Text] [Related]
6. Loss of heterozygosity for the short arm of chromosome 7 in sporadic Wilms tumour.
Grundy RG; Pritchard J; Scambler P; Cowell JK
Oncogene; 1998 Jul; 17(3):395-400. PubMed ID: 9690521
[TBL] [Abstract][Full Text] [Related]
7. Infrequent mutation of the WT1 gene in 77 Wilms' Tumors.
Gessler M; König A; Arden K; Grundy P; Orkin S; Sallan S; Peters C; Ruyle S; Mandell J; Li F
Hum Mutat; 1994; 3(3):212-22. PubMed ID: 8019557
[TBL] [Abstract][Full Text] [Related]
8. Altered expression of imprinted genes in Wilms tumors.
Hubertus J; Lacher M; Rottenkolber M; Müller-Höcker J; Berger M; Stehr M; von Schweinitz D; Kappler R
Oncol Rep; 2011 Mar; 25(3):817-23. PubMed ID: 21174059
[TBL] [Abstract][Full Text] [Related]
9. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
[TBL] [Abstract][Full Text] [Related]
10. Germline mutations of the POU6F2 gene in Wilms tumors with loss of heterozygosity on chromosome 7p14.
Perotti D; De Vecchi G; Testi MA; Lualdi E; Modena P; Mondini P; Ravagnani F; Collini P; Di Renzo F; Spreafico F; Terenziani M; Sozzi G; Fossati-Bellani F; Radice P
Hum Mutat; 2004 Nov; 24(5):400-7. PubMed ID: 15459955
[TBL] [Abstract][Full Text] [Related]
11. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
[TBL] [Abstract][Full Text] [Related]
12. Nephroblastoma (Wilms' tumor): a model system of aberrant renal development.
Re GG; Hazen-Martin DJ; Sens DA; Garvin AJ
Semin Diagn Pathol; 1994 May; 11(2):126-35. PubMed ID: 7809506
[TBL] [Abstract][Full Text] [Related]
13. [Genetics of renal tumors].
Oláh E; Jakab Z; Balogh E
Orv Hetil; 2001 Jul; 142(26):1367-73. PubMed ID: 11478032
[TBL] [Abstract][Full Text] [Related]
14. Loss of imprinting of IGF2 sense and antisense transcripts in Wilms' tumor.
Vu TH; Chuyen NV; Li T; Hoffman AR
Cancer Res; 2003 Apr; 63(8):1900-5. PubMed ID: 12702581
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of a 7p15-21 homozygous deletion in a Wilms tumor.
Sossey-Alaoui K; Vieira L; David D; Boavida MG; Cowell JK
Genes Chromosomes Cancer; 2003 Jan; 36(1):1-6. PubMed ID: 12461744
[TBL] [Abstract][Full Text] [Related]
16. Frequency and timing of loss of imprinting at 11p13 and 11p15 in Wilms' tumor development.
Brown KW; Power F; Moore B; Charles AK; Malik KT
Mol Cancer Res; 2008 Jul; 6(7):1114-23. PubMed ID: 18644976
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M
Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575
[TBL] [Abstract][Full Text] [Related]
18. Molecular analysis of E-cadherin and cadherin-11 in Wilms' tumours.
Schulz S; Becker KF; Braungart E; Reichmuth C; Klamt B; Becker I; Atkinson M; Gessler M; Höfler H
J Pathol; 2000 Jun; 191(2):162-9. PubMed ID: 10861576
[TBL] [Abstract][Full Text] [Related]
19. Effects of chemotherapy on the cytogenetic constitution of Wilms' tumor.
Schlomm T; Gunawan B; Schulten HJ; Sander B; Thangavelu K; Graf N; Leuschner I; Ringert RH; Füzesi L
Clin Cancer Res; 2005 Jun; 11(12):4382-7. PubMed ID: 15958621
[TBL] [Abstract][Full Text] [Related]
20. Paternally inherited submicroscopic duplication at 11p15.5 implicates insulin-like growth factor II in overgrowth and Wilms' tumorigenesis.
Algar EM; St Heaps L; Darmanian A; Dagar V; Prawitt D; Peters GB; Collins F
Cancer Res; 2007 Mar; 67(5):2360-5. PubMed ID: 17325026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
